102309-64-8Relevant academic research and scientific papers
Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor
McDaniel, Keith F.,Wang, Le,Soltwedel, Todd,Fidanze, Steven D.,Hasvold, Lisa A.,Liu, Dachun,Mantei, Robert A.,Pratt, John K.,Sheppard, George S.,Bui, Mai H.,Faivre, Emily J.,Huang, Xiaoli,Li, Leiming,Lin, Xiaoyu,Wang, Rongqi,Warder, Scott E.,Wilcox, Denise,Albert, Daniel H.,Magoc, Terrance J.,Rajaraman, Ganesh,Park, Chang H.,Hutchins, Charles W.,Shen, Jianwei J.,Edalji, Rohinton P.,Sun, Chaohong C.,Martin, Ruth,Gao, Wenqing,Wong, Shekman,Fang, Guowei,Elmore, Steven W.,Shen, Yu,Kati, Warren M.
supporting information, p. 8369 - 8384 (2017/11/03)
The development of bromodomain and extraterminal domain (BET) bromodomain inhibitors and their examination in clinical studies, particularly in oncology settings, has garnered substantial recent interest. An effort to generate novel BET bromodomain inhibi
BROMODOMAIN INHIBITORS
-
Page/Page column 59; 104, (2013/07/19)
Provided are compounds of formula (I), wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
